Cell therapies in bladder cancer management
L Morales, JM Paramio - International Journal of Molecular Sciences, 2021 - mdpi.com
Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology.
The high incidence, prevalence, and progression of BC have led to the exploration of new …
The high incidence, prevalence, and progression of BC have led to the exploration of new …
Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy
N Farooqui, JPT Sy-Go, J Miao, R Mehta… - Mayo Clinic …, 2022 - Elsevier
Objective To evaluate the association of baseline and postinfusion patient characteristics
with acute kidney injury (AKI) in the month after chimeric antigen receptor T-cell (CAR-T) …
with acute kidney injury (AKI) in the month after chimeric antigen receptor T-cell (CAR-T) …
Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in …
S Wakase, T Teshima, J Zhang, Q Ma… - … and Cellular Therapy, 2021 - Elsevier
Until recently, treatment options were relatively limited for children and young adults with
relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a …
relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a …
Short time to market and forward planning will enable cell therapies to deliver R&D pipeline value
There is considerable industry excitement about the curative potential of cell and gene
therapies, but significant challenges remain in designing cost-effective treatments that are …
therapies, but significant challenges remain in designing cost-effective treatments that are …